Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia

Atherosclerosis

Volumn 207, Issue 2, 2009, Pages 579-584

  Shoji, Tetsuo ^a   Hatsuda, Sawako ^a   Tsuchikura, Shoko ^a   Kimoto, Eiji ^a   Kakiya, Ryusuke ^b   Tahara, Hideki ^a   Koyama, Hidenori ^a   Emoto, Masanori ^a   Tabata, Tsutomu ^b   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Inoue Hospital   (Japan)

Author keywords

Angiopoietin like protein 3 (ANGPTL3); Chronic kidney disease (CKD); Dyslipidemia; Hemodialysis; Lipoprotein

Indexed keywords

ADIPONECTIN; ANGIOPOIETIN LIKE PROTEIN 3; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; PLASMA PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION; UREMIC DYSLIPIDEMIA;

ANGIOPOIETINS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; DYSLIPIDEMIAS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; ULTRACENTRIFUGATION; UREMIA;

EID: 70450284542     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.05.023     Document Type: Article

References (29)

1. Wanner C., and Krane V. Uremia-specific alterations in lipid metabolism. Blood Purif 20 (2002) 451-453
2. Shoji T., and Nishizawa Y. Plasma lipoprotein abnormalities in hemodialysis patients-clinical implications and therapeutic guidelines. Ther Apher Dial 10 (2006) 305-315
3. Shoji T., Nishizawa Y., Kawagishi T., et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 9 (1998) 1277-1284
4. Shoji T., Kawagishi T., Emoto M., et al. Additive impacts of diabetes and renal failure on carotid atherosclerosis. Atherosclerosis 153 (2000) 257-258
5. Shoji T., Emoto M., Tabata T., et al. Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int 61 (2002) 2187-2192
6. Shinohara K., Shoji T., Tsujimoto Y., et al. Arterial stiffness in predialysis patients with uremia. Kidney Int 65 (2004) 936-943
7. Savdie E., Gibson J.C., Crawford G.A., Simons L.A., and Mahony J.F. Impaired plasma triglyceride clearance as a feature of both uremic and posttransplant triglyceridemia. Kidney Int 18 (1980) 774-782
8. Ikewaki K., Schaefer J.R., Frischmann M.E., et al. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol 25 (2005) 2615-2622
9. Eisenberg S. High density lipoprotein metabolism. J Lipid Res 25 (1984) 1017-1058
10. Ibels S.L., Reardon M.F., and Nestel P.J. Plasma post-heparin lipolytic activity and triglyceride clearance in uremic and hemodialysis patients and renal allograft recipients. J Lab Clin Med 87 (1976) 648-658
11. Mordasini R., Frey F., Flury W., Klose G., and Greten H. Selective deficiency of hepatic triglyceride lipase in uremic patients. N Engl J Med 297 (1977) 1362-1366
12. Shoji T., Nishizawa Y., Koyama H., et al. High-density-lipoprotein metabolism during a very-low-calorie diet. Am J Clin Nutr 56 (1992) 297S-298S
13. Murase T., Cattran D.C., Rubenstein B., and Steiner G. Inhibition of lipoprotein lipase by uremic plasma, a possible cause of hypertriglyceridemia. Metabolism 24 (1975) 1279-1286
14. Koishi R., Ando Y., Ono M., et al. Angptl3 regulates lipid metabolism in mice. Nat Genet 30 (2002) 151-157
15. Kim I., Kim H.G., Kim H., et al. Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J 346 Pt 3 (2000) 603-610
16. Shimizugawa T., Ono M., Shimamura M., et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem 277 (2002) 33742-33748
17. Shimamura M., Matsuda M., Kobayashi S., et al. Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. Biochem Biophys Res Commun 301 (2003) 604-609
18. Shoji T., Nishizawa Y., Kawagishi T., et al. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 131 (1997) 229-236
19. Shoji T., Emoto M., Kawagishi T., et al. Atherogenic lipoprotein changes in diabetic nephropathy. Atherosclerosis 156 (2001) 425-433
20. Hatsuda S., Shoji T., Shinohara K., et al. Association between plasma angiopoietin-like protein 3 and arterial wall thickness in healthy subjects. J Vasc Res 44 (2007) 61-66
21. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
22. Emoto M., Nishizawa Y., Maekawa K., et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 22 (1999) 818-822
23. Olivecrona T., Bengtsson-Olivecrona G., Osborne Jr. J.C., and Kempner E.S. Molecular size of bovine lipoprotein lipase as determined by radiation inactivation. J Biol Chem 260 (1985) 6888-6891
24. Ikeda Y., Takagi A., and Yamamoto A. Purification and characterization of lipoprotein lipase and hepatic triglyceride lipase from human postheparin plasma: production of monospecific antibody to the individual lipase. Biochim Biophys Acta 1003 (1989) 254-269
25. Havel R.J., Fielding C.J., Olivecrona T., Shore V.G., Fielding P.E., and Egelrud T. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources. Biochemistry 12 (1973) 1828-1833
26. Shachter N.S., Hayek T., Leff T., et al. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest 93 (1994) 1683-1690
27. Shimamura M., Matsuda M., Yasumo H., et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler Thromb Vasc Biol 27 (2007) 366-372
28. Miida T., Seino U., Miyazaki O., et al. Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling. Atherosclerosis 200 (2008) 329-335
29. Moon H.D., Nakajima K., Kamiyama K., Takanashi K., Sakurabayashi I., and Nagamine T. Higher frequency of abnormal serum angiopoietin-like protein 3 than abnormal cholesteryl ester transfer protein in Japanese hyperalphalipoproteinemic subjects. Clin Chim Acta 398 (2008) 99-104